Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Paul Brannelly currently holds 221,355 shares of Karyopharm Therapeutics Inc. (KPTI), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Paul Brannelly has been a net seller of KPTI stock. They have purchased $159.6K and sold $444.2K worth of shares.
Paul Brannelly's most recent insider trade was on Feb 10, 2021, when they sold 2,564 shares at $25.95 per share.
Paul Brannelly serves as Executive at Karyopharm Therapeutics Inc. (KPTI). They have executed 93 insider transactions totaling $603.8K over their tenure at the company.
Paul Brannelly holds the position of Executive at Karyopharm Therapeutics Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 18 years and currently hold a stake valued at $0.
Paul Brannelly has shown a selling trading pattern, with $159.6K in total purchases and $444.2K in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Paul Brannelly was on Feb 10, 2021, when they sold $153.8K worth of COLL shares. This transaction involved 5,927 shares at $25.95 per share.
Paul Brannelly currently owns 221,355 shares of Karyopharm Therapeutics Inc. (KPTI), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Paul Brannelly's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Paul Brannelly has 93 Form 4 filings on record as an insider at Karyopharm Therapeutics Inc..
Set alerts for Paul Brannelly and 40,000+ other insiders.